Research
Isis Begins Phase III Clinical Trial
On August 1, Isis Pharmaceuticals, Inc. announced today the initiation of a pivotal Phase III study evaluating ISIS-SMNRx in infants with spinal muscular atrophy (SMA). […]
Cure SMA Announces New Research Funding
Cure SMA is proud to announce that we will be committing $1.8 million to new research funding over the next 12 months. Fifteen years ago, […]
- « Previous
- 1
- …
- 40
- 41
- 42